Elicio Therapeutics announces additional data from Phase 2 AMPLIFY-7P trial

Elicio Therapeutics (ELTX) announced additional immunogenicity data from the ongoing Phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in patients with mKRAS pancreatic ductal adenocarcinoma, PDAC, and new preclinical data on immunotherapy candidate ELI-004, for treatment of solid tumors. The data will be presented at the Society for Immunotherapy of Cancer 2025 Annual Meeting. Poster 1: Among 90 evaluable patients treated with ELI-002 7P in the ongoing Phase 2 AMPLIFY-7P trial, 99% achieved robust mKRAS-specific T cell responses, with a mean145-fold increase over baseline. Consistent and broad immunogenicity was observed, with 85% of patients showing combined CD4 and CD8 T cell activation-previously correlated with clinical activity-and 86% of mKRAS target antigens eliciting immune responses. Poster 2: Therapeutic treatment of established solid tumors in mice with intratumoral ELI-004 induced complete eradication of tumors in greater than90% of cases; complete responders were protected from subsequent tumor recurrence 3-5 months following initial therapy suggesting robust development of immunological memory. Tumor response and full eradication were dependent upon the presence of CD8 T cells and effective trafficking of lymphocytes from lymph nodes, respectively, indicating a role of ELI-004 for initiation and support of local anti-tumor immune responses alongside induction of systemic immune responses in secondary lymphoid organs.